Marketing - Press Releases

Date	Title	Company
17-May-2022	IMFINZI (durvalumab) ACCEPTED FOR ROUTINE USE WITHIN NHS ENGLAND FOR ADULTS WITH STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER	AstraZeneca
13-May-2022	Tower Cold Chain sets sights on doubling its global network as L.A. hub opens	Tower Cold Chain
12-May-2022	This move is important to you. To support you to get that job, PharmiWeb.Jobs are delighted to announce they’ve partnered with CareerJay	CareerJay, PharmiWeb
14-Apr-2022	Global Wealth Management Platform Market worth US$ 7.6 Billion 2029 with a CAGR of 13.2%	Prophecy Market Insights
12-Apr-2022	Global Smoke Evacuation Systems Market, By Product, Share, Outlook, Forecast 2022-2028	Blueweave Consulting
06-Apr-2022	FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA	SMi Group
05-Apr-2022	AXON hires a Global Healthcare Insights and Strategy Lead	AXON
05-Apr-2022	Global Healthcare IoT Security Market worth US$ 24.57 Billion 2020 with a CAGR of 35.70%	https://www.prophecymarketinsights.com/
04-Apr-2022	CPHI North America opens as 65% of US companies forecast growth in excess of 20% in 2022	CPHI North America
25-Mar-2022	Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody	Tiziana Life Sciences Ltd
25-Mar-2022	Envirotainer’s Releye® RAP container already approved by 10 airlines	Envirotainer
21-Mar-2022	Creative Enzymes Probiotics Expands Service Offering with the Launch of Lactobacillus Strains	Creative Enzymes
10-Mar-2022	konectar Social - connect with right DOLs	Aissel Technologies Inc
08-Mar-2022	Rapid Microbial Methods, Contamination Control, Sterility Assurance and Environmental Monitoring to be covered at Microbiology East Coast Conference in Boston	SMi Group
05-Mar-2022	Exclusive Chemaxon Interview released - Sponsor at AI in Drug Discovery Conference 2022	SMi Group
23-Feb-2022	New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks	Janssen
23-Feb-2022	Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone	Janssen
23-Feb-2022	The Majority of Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA®▼ (guselkumab)	Janssen
22-Feb-2022	Europe’s Only Parallel Trade Conference returns for its 16th Year	SMi Group
09-Feb-2022	Book to attend the Parallel Trade conference before seats are filled	SMi Group